Proprietary AI analyst is now available

Zhuhai Huajin Capital Co Valuation Multiples

Discover Zhuhai Huajin Capital Co's revenue and EBITDA valuation multiples and investment history, alongside public comparables like Integral, Beltone Holding, Foresight Gr Hldgs, Spiltan Invest and more.

Zhuhai Huajin Capital Co Overview

About Zhuhai Huajin Capital Co

Zhuhai Huajin Capital Co Ltd is engaged in the asset management business. It has its investments in medical health, internet, cultural media, energy conservation, and others.


Founded

1992

HQ

China

Employees

911

Sectors

Financials (FY)

Revenue: $73M
EBITDA: $44M

EV

$592M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Zhuhai Huajin Capital Co Financials

Zhuhai Huajin Capital Co reported last fiscal year revenue of $73M and EBITDA of $44M.

In the same fiscal year, Zhuhai Huajin Capital Co generated $33M in gross profit, $44M in EBITDA, and $24M in net income.


Zhuhai Huajin Capital Co P&L

In the most recent fiscal year, Zhuhai Huajin Capital Co reported revenue of $73M and EBITDA of $44M.

Zhuhai Huajin Capital Co is profitable as of last fiscal year, with gross margin of 45%, EBITDA margin of 61%, and net margin of 33%.

See analyst estimates for Zhuhai Huajin Capital Co
Last FY202320242025202620272028
Revenue$73M$59M$72M$73M
Gross Profit$33M$25M$37M$33M
Gross Margin45%42%51%45%
EBITDA$44M$24M$50M$44M
EBITDA Margin61%41%69%61%
EBIT Margin29%23%37%29%
Net Profit$24M$11M$23M$24M
Net Margin33%18%32%33%

Financial data powered by Morningstar, Inc.

Zhuhai Huajin Capital Co Stock Performance

Zhuhai Huajin Capital Co has current market cap of $613M, and enterprise value of $592M.


Zhuhai Huajin Capital Co's stock price is $1.78.

Zhuhai Huajin Capital Co has an EPS (earnings per share) of $0.07.

See more trading valuation data for Zhuhai Huajin Capital Co
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$592M$613M0.3%---$0.07

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Zhuhai Huajin Capital Co Valuation Multiples

Zhuhai Huajin Capital Co trades at 8.1x EV/Revenue multiple, and 13.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Zhuhai Huajin Capital Co

Zhuhai Huajin Capital Co Financial Valuation Multiples

As of June 17, 2026, Zhuhai Huajin Capital Co has market cap of $613M and EV of $592M.

Zhuhai Huajin Capital Co has a P/E ratio of 25.4x.

Last FY202320242025202620272028
EV/Revenue8.1x10.0x8.2x8.1x
EV/EBITDA13.3x24.5x11.9x13.3x
EV/EBIT27.7x43.4x22.5x27.7x
EV/Gross Profit17.8x23.5x16.1x17.8x
P/E25.4x56.0x26.5x25.4x
EV/FCF25.0x44.4x31.2x25.0x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Zhuhai Huajin Capital Co Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Zhuhai Huajin Capital Co Margins & Growth Rates

In the most recent fiscal year, Zhuhai Huajin Capital Co reported gross margin of 45%, EBITDA margin of 61%, and net margin of 33%.

See estimated margins and future growth rates for Zhuhai Huajin Capital Co

Zhuhai Huajin Capital Co Margins

Last FY20242025202720282029
Gross Margin45%51%45%
EBITDA Margin61%69%61%
EBIT Margin29%37%29%
Net Margin33%32%33%
FCF Margin32%26%32%

Zhuhai Huajin Capital Co Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth21%2%
Gross Profit Growth46%(10%)
EBITDA Growth106%(11%)
EBIT Growth93%(19%)
Net Profit Growth112%4%
FCF Growth42%25%

Data powered by FactSet, Inc. and Morningstar, Inc.

Zhuhai Huajin Capital Co Operational KPIs

Zhuhai Huajin Capital Co's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.

Access forward-looking KPIs for Zhuhai Huajin Capital Co
Last FY202320242025202620272028
Revenue per Employee$0.1M---
Opex per Employee$0.0M---
S&M Expenses to Revenue0%0%0%0%
G&A Expenses to Revenue2%3%2%2%
R&D Expenses to Revenue4%2%2%4%
Opex to Revenue16%19%14%16%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Zhuhai Huajin Capital Co Competitors

Zhuhai Huajin Capital Co competitors include Integral, Beltone Holding, Foresight Gr Hldgs, Spiltan Invest, Senvest Capital, Pollen Street Group, CBRE Clarion Glb Real Est, RTW Biotech Opportunities, Front Ventures and Deutsche Beteiligungs.

Most Zhuhai Huajin Capital Co public comparables operate across PE & VC.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Integral5.9x5.9x8.5x-
Beltone Holding4.0x-29.5x-
Foresight Gr Hldgs3.0x2.7x7.2x6.6x
Spiltan Invest45.1x-(20.5x)-
Senvest Capital1.9x---
Pollen Street Group5.4x5.2x11.6x11.2x
CBRE Clarion Glb Real Est54.7x---
RTW Biotech Opportunities2.9x---

This data is available for Pro users. Sign up to see all Zhuhai Huajin Capital Co competitors and their valuation data.

Start Free Trial

Investments by Zhuhai Huajin Capital Co

Zhuhai Huajin Capital Co has invested in 33 companies to date.

Latest investment by Zhuhai Huajin Capital Co was on June 7th 2026. Zhuhai Huajin Capital Co invested in Dongsheng Fusion in their $100M Seed round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Zhuhai Huajin Capital Co

Dongsheng Fusion
Zhide New Energy
XellSmart
Baoling Bio
Description
Dongsheng Fusion advances magnetic confinement fusion technology for miniaturized power plants.
Zhide New Energy is a developer of silicon anode materials for batteries, producing high-energy-density, low-cost solutions for electric vehicles, consumer electronics, home power storage, and wearable devices.
XellSmart is a biotechnology company advancing stem cell therapies for degenerative diseases including osteoarthritis and neurological disorders. Shanghai-headquartered in Minhang District, the firm conducts preclinical and clinical trials using induced pluripotent stem cells differentiated into targeted tissue types. XellSmart collaborates with Chinese research institutions to develop allogeneic cell products for unmet clinical needs.
Baoling Bio is a biotechnology firm specializing in research, development, and industrialization of novel therapeutics. Its pipeline targets solid tumors, hematologic cancers, autoimmune disorders, and cytokine release syndrome linked to COVID-19 pneumonia. The company advances small-molecule drugs and biologics from discovery through clinical stages, partnering with contract manufacturers for large-scale production in China.
HQ CountryChinaChinaChinaChina
HQ City
-
-
Shanghai
Chengdu
Deal Date7 Jun 20268 Apr 202631 Mar 202612 Jan 2026
RoundSeedSeries ESeries CSeries C
Raised$100M$87M$73M$86M
InvestorsBaidu Capital; CAS Star; CMC Capital Group; Fibonacci VC; Fortune Venture Capital; Huafu Growth Capital; Zhuhai Huajin Capital Co; ICBC Capital; Lanxi Capital; Orient Securities; Qianhai Ark; Qiming Venture PartnersChina Securities Investment; Fortune Venture Capital; Zhuhai Huajin Capital Co; Yunhao Capital; Sparkedge CapitalSuzhou Angel Fund of Funds; Qisheng Capital; Xinyi Capital; Haiwang Capital; Zhuhai Huajin Capital Co; Frees Fund; Sincere Capital; Shanghai Pudong Haitong Fund; Innotek; China National Venture Capital; BOC Capital; Shanghai Minjin Investment5Y Capital; Guosheng Capital; Zhuhai Huajin Capital Co; Lanchi Ventures; Qiming Venture Partners; Shanghai Science and Technology Innovation Fund; Sichuan Science and Technology Innovation Investment Group; Tengxun Touzi; TrueLight Capital; Xiamen C&D Emerging Industry Equity Investment
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Zhuhai Huajin Capital Co investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Zhuhai Huajin Capital Co

When was Zhuhai Huajin Capital Co founded?Zhuhai Huajin Capital Co was founded in 1992.
Where is Zhuhai Huajin Capital Co headquartered?Zhuhai Huajin Capital Co is headquartered in China.
How many employees does Zhuhai Huajin Capital Co have?As of today, Zhuhai Huajin Capital Co has over 911 employees.
Is Zhuhai Huajin Capital Co publicly listed?Yes, Zhuhai Huajin Capital Co is a public company listed on Shenzhen Stock Exchange.
What is the stock symbol of Zhuhai Huajin Capital Co?Zhuhai Huajin Capital Co trades under 000532 ticker.
When did Zhuhai Huajin Capital Co go public?Zhuhai Huajin Capital Co went public in 1994.
Who are competitors of Zhuhai Huajin Capital Co?Zhuhai Huajin Capital Co main competitors include Integral, Beltone Holding, Foresight Gr Hldgs, Spiltan Invest, Senvest Capital, Pollen Street Group, CBRE Clarion Glb Real Est, RTW Biotech Opportunities, Front Ventures, Deutsche Beteiligungs.
What is the current market cap of Zhuhai Huajin Capital Co?Zhuhai Huajin Capital Co's current market cap is $613M.
What is the current revenue of Zhuhai Huajin Capital Co?Zhuhai Huajin Capital Co's last fiscal year revenue is $73M.
What is the current EV/Revenue multiple of Zhuhai Huajin Capital Co?Current revenue multiple of Zhuhai Huajin Capital Co is 8.1x.
Is Zhuhai Huajin Capital Co profitable?No, Zhuhai Huajin Capital Co is not profitable.
How many companies Zhuhai Huajin Capital Co has acquired to date?Zhuhai Huajin Capital Co hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Zhuhai Huajin Capital Co has invested to date?As of June 2026, Zhuhai Huajin Capital Co has invested in 33 companies.
What was the last Zhuhai Huajin Capital Co investment?On 7th June 2026 Zhuhai Huajin Capital Co invested in Dongsheng Fusion, participating in a $100M Seed round, alongside Baidu Capital, CAS Star, CMC Capital Group, Fibonacci VC, Fortune Venture Capital, Huafu Growth Capital, ICBC Capital, Lanxi Capital, Orient Securities, Qianhai Ark, and 1 other investor.
In what companies Zhuhai Huajin Capital Co invested in?Zhuhai Huajin Capital Co invested in WeRide, Mabwell, Huali Juneng, Singularity Energy Technology, Dongsheng Fusion, CYGNUSEMI, Zhide New Energy, Baoling Bio, Guizhou Core Long March Technology (Marching Power), XellSmart, Norson Biotechnology, MabPlex International, MingMed, Anmuquan Intelligent Technology, Arnatar Therapeutics, Beilai Bio, Kintor Pharmaceutical, Aiste, Arashi Vision, Genepoint Biological Technology, and 13 other companies.

See public comps similar to Zhuhai Huajin Capital Co

Lists including Zhuhai Huajin Capital Co

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial